Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2015

View Archived Issues

HIV Vaccine Trials Network launches phase I/II trial of prime-boost vaccine

IDRI receives BARDA funding to establish adjuvant hub

E Keppra approved in Japan as monotherapy for partial-onset seizures

Queen Mary University of London and Takeda to develop new gastroenterology therapies

Cerecor acquires kappa opioid receptor antagonist from Eli Lilly

Anti-IL-23 antibody shows clinical effect in Crohn's disease patients

Vichem Chemie Research discloses new FLT3 inhibitors

Anti-MZGP2 antibodies associated with Crohn's disease phenotypes

Actelion Pharmaceuticals patents new lipoxin receptor agonists

Roche patent reports new fusion proteins for Alzheimer's type dementia

New SHIP-2 inhibitors for diabetes designed by University of Toyama

Merck KGaA discloses multiple kinase inhibitors

Novo Nordisk reports positive results from phase II trial of oral semaglutide in type 2 diabetes

Valeant to acquire Salix Pharmaceuticals

Investigators prepare new anti-GARP MAbs

Allergan patents S1P1 receptor ligands

Sosei acquires Heptares Therapeutics

FDA grants orphan drug status to polidocanol for venous malformations

FDA grants priority review to Rapamune sNDA for lymphangioleiomyomatosis

AB-Biotics collaborates with Derbycare to launch AB-Kolicare in China

Shire completes acquisition of NPS Pharmaceuticals

First stem cell-based medicinal product approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...